The immunogenicity of virus-derived 2A sequences in immunocompetent individuals by Arber, C. et al.
The immunogenicity of virus-derived 2A sequences in
immunocompetent individuals
C Arber1, H Abhyankar1, HE Heslop1,2,3, MK Brenner1,2,3, H Liu1,4, G Dotti1,2,5, and B
Savoldo1,3
1Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and
Texas Children's Hospital, Houston, TX, USA
2Department of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX,
USA
3Department of Pediatrics, The Methodist Hospital and Texas Children's Hospital, Houston, TX,
USA
4Department of Biostatistics Shared Resource Dan L. Duncan Cancer Center, The Methodist
Hospital and Texas Children's Hospital, Houston, TX, USA
5Department of Immunology, Baylor College of Medicine, The Methodist Hospital and Texas
Children's Hospital, Houston, TX, USA.
Abstract
Genetic engineering of T cells for adoptive immunotherapy in cancer patients has shown
significant promise. To ensure optimal antitumor activity and safety, the simultaneous expression
of multiple genes is frequently required, and short viral-derived 2A sequences are increasingly
preferred for this purpose. Concerns exist, however, that these virus-derived sequences may
induce unwanted immune responses, and thus diminish persistence of the gene-modified cells after
adoptive transfer. Whereas such responses were absent in immunocompromised recipients,
potential immunogenicity in immunocompetent individuals remains a concern. We now address
whether ex vivo T cell responses can be elicited against the most widely used 2A sequences (2A-
Thosea asigna virus (TAV) or 2A-equine rhinitis virus (ERAV), specifically) in
immunocompetent individuals. We used a potent ex vivo culture system previously validated to
induce T cell responses even against weakly immunogenic antigens. Of the sixteen donors tested,
only five released very low levels of interferon-γ in response to 2A-TAV peptide mixtures (single
peptide specificity in three donors, adjacent self-antigen peptide specificity in one donor and
nonspecific reactivity in one donor). None of them produced cytotoxic activity or responded to
2A-ERAV. These results suggest that exposure to viral-derived 2A sequences is unlikely to
produce unwanted T cell responses in immunocompetent individuals and further supports their
continued use for studies of human gene therapy.
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Adoptive T cell-based immunotherapies and vaccines are promising approaches for cancer
patients, and genetic engineering can significantly improve their potency.1,2 Efficient
expression of multiple genes in one single polycistronic vector can simultaneously
coordinate the expression of multiple components of the immune system against cancer cells
and counterbalance tumor immune evasion mechanisms,3 and is often critical for the success
of these therapies. For example, production of T lymphocytes that will safely and efficiently
kill tumor cells after adoptive transfer may require simultaneous genetic modifications to
increase their tumor specificity by forced expression of engineered T cell receptors;2,4
enhance their trafficking by expression of chemokine receptors;4,5 prolong their persistence
by forced expression of cytokines or co-stimulatory molecules6–11 and augment safety by
the incorporation of a suicide switch to remove gene-modified cells on demand.12,13
Of the available strategies to generate polycistronic vectors, virus-derived 2A sequences are
one of the most effective.14 These sequences are cis-acting hydrolase elements that mediate
a ribosomal skip between 2A-linked genes,15 resulting in stoichiometric protein
production16 that can improve transgene expression and function, for example, of T cells
engineered with transgenic αβT cell receptors.17 Moreover, 2A sequences are quite short
(54–60 nucleotides), and therefore have little impact on vector-packaging limits. However,
as the 2A sequences are of viral origin, their expression in fusion proteins could lead to the
expression of immunogenic epitopes and thereby diminish the in vivo persistence of
corresponding gene-modified cells.
Recently, 2A sequences have been successfully incorporated in vectors used in human
studies without eliciting discernible immune responses, although the recipients in these trials
were significantly immunocompromised.13,17 Thus, to discover whether virus-derived 2A
sequences may cause troublesome immunogenicity in immunocompetent individuals, we
assessed if T cell responses could be elicited to protein regions derived from two vectors
containing either the 2A-TAV (Those asigna virus-derived)13 or the 2A-ERAV (equine
rhinitis virus-derived)7 sequences. We used a potent ex vivo culture system that has been
previously optimized to expand T cells with specificity for weak antigens, even from
antigenically naive individuals,18 such as umbilical cord blood T cells.19 Our results support
the continued exploration of 2A sequences even in immunocompetent human subjects.
RESULTS AND DISCUSSION
Using our optimized culture system,18–20 we successfully generated T cell lines from normal
adult donors that had robust interferon-γ (IFN-γ) production in response to the
cytomegalovirus-derived pp65 peptide mixture (pepmix) (1274.6±91.9 IFN-γ spot-forming
cells (SFCs) per 105 cells) in 7/7 donors (Figure 1a) and to the weak tumor-associated
antigen, preferentially expressed antigen of melanoma (PRAME) pepmix18 (409.1±29.7
IFN-γ SFCs per 105 cells) in 8/9 donors (Figure 1b). By contrast, when we used the same
culture conditions with peptide mixtures derived from the two 2A sequences, we found
minimal reactivity against the 2A-TAV pepmix in only 5 of the 16 donors tested (59.6±6.7
IFN-γ SFCs per 105 cells) (Figure 1c), and no discernible responses against the 2A-ERAV-
pepmix in any of the 11 donors tested (Figure 1d). Phenotypically, all lines were a mixture
of CD4+ and CD8+ cells, and contained some natural killer cells, with a trend (P=0.07) for a
lower proportion of CD8+ cells in the 2A-TAV and 2A-ERAV lines (for 2A-TAV:
CD8+=48.6±23.1%; for 2A-ERAV: CD8+=48.5±20.32%), as compared with pp65-specific
T cell lines (CD8+=70.4±12.8%) or with PRAME-specific T cell lines (CD8+=58.8±19.7%,
Figure 2).
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To identify the weakly immunogenic peptides derived from the 2A-TAV sequence, we
tested each of the 11 single 15-mer peptides against the five weakly reactive T cell lines.
Three of these five lines (derived from donor nos. 13, 14 and 15, Figure 3a) released IFN-γ
upon exposure to the RAEGRGSLLTCGDVE peptide (51.9±6.9 IFN-γ SFCs per 105 cells,
peptide no. 5 of the pool, Figure 4a). The line from donor no. 9 (Figure 3a) reacted against
the CFNFLRKKLFFKTSA peptide (57.3±10.3 IFN-γ SFCs per 105 cells, peptide no. 1 of
the pool, Figure 4a) and simultaneously against the PRLLFFLLFLTPMEV peptide
(21.0±15.1 IFN-γ SFCs per 105 cells, peptide no. 11 of the pool, Figure 4a). These are
junctional peptides between the 2A sequence, and the carboxyand amino-terminal sequences
of the expressed genes of interest (human inducible caspase9 and the signal peptide
sequence of human CD19, respectively). The line derived from donor no. 8 was responsive
against the 2A-TAV pepmix, but had no discernible reactivity to any of the individual
peptides contained in the mixture and was thus classified as nonspecific.
To discover the associated biological consequences of the low-level IFN-γ responses seen in
the four antigen-specific T cell lines, we measured their cytotoxic properties using the
CD107a/b degranulation assay. All these lines responded appropriately to polyclonal
stimulation with phorbol myristate acetate and ionomycin (66±13% CD107a/b+ CD3+ cells),
and therefore had functional potential, but no specific degranulation was detected upon
stimulation with the 2A-TAV pepmix (2.5±0.5% CD107a/b+ CD3+ cells) or the specific
single peptide no. 5 (1.7±0.5% CD107a/b+ CD3+ cells for lines from donor nos. 13–15), as
compared with the negative control (2A-ERAV-pepmix, 2.2±1% CD107a/b+ CD3+ cells)
(Figures 3b and c, P=NS), consistent with the minimal reactivity shown in the IFN-γ
ELISpot assay (Figures 1c and 3a). As expected, pp65-specific- and PRAME-reactive lines
specifically degranulated on exposure to the corresponding pp65 or PRAME pepmixes
(13.3±12.2% CD107a/b+ CD3+ cells, n=9), but not to control peptides (2A-ERAV-pepmix,
2.7±1.4% CD107a/b+ CD3+ cells) (Figures 3b and c, P=0.03).
We next assessed whether T cells transduced with the 2A-TAV-containing retroviral vector,
SFG.iCasp9.2A-TAV.ΔCD19, could present and process any of these epitopes. Autologous
T cells from the reactive donor nos. 9, 13, 14 and 15 were transduced
(CD3+CD19+=53.7±11.5%) (Figure 3d) and then used as targets in a standard
6-h 51Chromium (Cr)-release assay. No significant lysis of 2A-TAV transduced (TD) or
non-transduced autologous target T cells was observed in any of the donors tested
(3.5±2.9% specific lysis against NT, 3.75±3.9% specific lysis against TD T cells, effector to
target ratio (E:T) 20:1) (Figure 3e).
Thus, our potent ex vivo culture system shows that the viral-derived 2A-TAV and 2A-
ERAV ribosomal skip sequences, and adjacent fusion protein regions exhibit very low (n=5)
to absent (n=11) immunogenicity in 16 healthy donors. That this paucity of response is
genuine rather than a reflection of deficiencies in our detection system is demonstrated by
the anticipated high level of reactivity against cytomegalovirus-derived antigens (7/7) or
weak tumor antigens (8/9), and by our ability to generate an expected low frequency (1/16)
of lines weakly reactive with peptides derived from the self-antigens linked by the 2A
sequences (human caspase9 and CD19) that were also included in the peptide mixtures. Of
note, the three donors with low-level reactivity to the peptide no. 5 of the 2A-TAV sequence
(donors no. 13–15) shared the same class-I-restricted human leukocyte antigen (HLA)
alleles (HLA-A*02 and HLA-B*44) and certain class-II haplotypes, including HLA-
DRB1*04, HLA-DQB1*03 (Table 1). These findings suggest that the reactive peptide no. 5
of the SFG.iCasp9.2A-TAV.ΔCD19 retroviral vector could contain an HLA class-I or class-
II epitope presented in the context of either of these HLA molecules. Given the overall low
level of reactivity of these lines, we could not further dissect these reactivities, and precisely
identify the epitope and its HLA context. The epitope prediction algorithms from
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SYFPEITHY (http://www.syfpeithi.de/) and the BioInformatics and Molecular Analysis
Section, NIH, (http://www-bimas.cit.nih.gov/molbio/hla_bind/) failed to indicate a
significantly high-scoring epitope within the 2A-TAV sequence in the context of HLA-
A*0201, HLA-A*0205, HLA-B*4402, HLA-B*4403 or HLADRB1*0401 (data not shown,
HLA-DQB1 epitopes are not available for prediction). Instead, the only epitope scoring
significantly high in both prediction algorithms in the context of the HLA-A*0201 molecule
was contained within the sequence of peptide no. 11 of the SFG.iCasp9.2A-TAV.ΔCD19
retroviral vector, which was recognized by the line derived from the HLA-A*02+ donor no.
9, and corresponded to the signal peptide of the human CD19 self-antigen (Figures 3a and
4a). Nonetheless, 7 of the 11 HLA-A*02+ donors failed to generate responses against such
epitopes.
Adoptive T cell therapy in cancer patients aims to generate a long-term persistence of the
transferred gene-modified T cells. This can be undermined if vectors contain potentially
immunogenic sequences, and TD cells are infused in immuno-competent individuals or if
multiple T cell administrations are performed. In these situations, in vivo sensitization
against vector components can be induced and result in the immune-mediated elimination of
the TD cells. No ex vivo system can fully reproduce the in vivo situation of a ‘booster
vaccination’ effect, but we have attempted to answer immunogenicity concerns in our in
vitro culture system by using three antigen-specific stimulations with professional antigen-
presenting cells (dendritic cells) to amplify T cell responses from immunocompetent
individuals. No significant cytotoxic activity was observed in the 16 donors tested, although
this limited sample size means we cannot exclude a true positive rate of up to 0.17.
Only clinical trials that include these 2A sequences in immunocompetent individuals can
definitely address the issue of their immunogenicity. However, the minimal reactivity we
observed to the 2A-TAV sequence (in terms of IFN-γ production) associated with the lack
of cytotoxic activity, as measured by the CD107a/b degranulation, seems unlikely to result
in significant biological consequences, particularly as we found no evidence that these
peptides could even be naturally processed and presented by T cells. In conclusion, our data
suggest that the incorporation of 2A sequences in polycistronic vectors should not
precipitate unwanted immune responses against the TD cells. Of the two 2A sequences
studied, 2A-ERAV may be even less immunogenic than 2A-TAV. Careful monitoring for
potential immunogenicity in future clinical trials with diverse patients and vectors will,
however, still be required before we can be certain that there is no effective 2A-directed
immune response against the TD T cells.
MATERIALS AND METHODS
Peptides and pepmixes
Fifteen-mer peptides overlapping by 11 amino acids spanning the 2A-TAV peptide sequence
region of the SFG.iCasp9.2A-TAV.ΔCD19 retroviral vector21 (Figure 4a) and the 2A-
ERAV peptide sequence of the SFG.iCasp9.2A-TAV.CAR-CD19-28ζ.2A-ERAV.IL
(interleukin)-15 retroviral vector7 (Figure 4b) were synthesized by JPT Peptide
Technologies (Berlin, Germany). Lyophilized peptides were reconstituted in dimethyl
sulfoxide and then pooled into peptide mixtures (pepmixes) containing all the 11 peptides
(2A-TAV mix or 2A-ERAV mix; 10 mg ml–1) or stored as single peptides (10 mg ml–1).
The pepmixes or single peptides were used to pulse dendritic cells, as previously
described.18 Pepmixes spanning the cytomegalovirus pp65 protein or the cancer testes
antigen PRAME (JPT Peptide Technologies) were used as controls.18,20
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Generation and expansion of peptide-specific T cell lines
Buffy coats from healthy volunteer blood donors were obtained through the Gulf Coast
Regional Blood Center, Houston, TX, USA. HLA typing of these samples was performed by
the HLA, Flow and Diagnostic Immunology Laboratory of the Department of Laboratory
Medicine at The Methodist Hospital, Houston, TX, USA, using PCR-SSO DNA-based
procedures. Peripheral blood mononuclear cells were isolated by Lymphoprep (Accurate
Chemical and Scientific Corp, Westbury, NY, USA) density gradient centrifugation.
Dendritic cells were generated as previously described,18 starting from CD14-selected cells
and, after maturation, pulsed with 5 μM of the specific pepmix for 2 h at 37 °C and finally
used to stimulate peripheral blood mononuclear cells at an E:T ratio of 20:1 in complete
media, containing 45% Click's media (Irvine Scientific, Santa Ana, CA, USA), 45% RPMI
1640 (HyClone Laboratories, Logan, Utah), 5% heat-inactivated human AB serum (Valley
Biomedical, Winchester, VA, USA), 1% L-glutamine and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA) in the presence of a previously validated combination of
cytokines (IL-7 (10 ng ml–1), IL-12 (1 ng ml–1) and IL-15 (2 ng ml–1) (all from Peprotec,
Rocky Hill, NJ, USA or R&D Systems, Minneapolis, MN, USA).18 On days 9 and 16 of
culture, T cells were re-stimulated with pepmix-pulsed dendritic cells at an E:T ratio of 10:1
in media containing IL-7, IL-12 and IL-15. IL-2 (50 U ml–1) was added to the culture from
day 16.
Retroviral transduction
The retroviral supernatant encoding the SFG.iCasp9.2A-TAV.ΔCD19 vector was prepared
as previously described.13 Peripheral blood mononuclear cells from donors 9, 13, 14 and 15
were activated with immobilized OKT3 and anti-CD28 (BD) antibodies, and IL-2 100 U
ml–1. After 72 h, cells were transduced on retronectin-coated plates (Takara Bio Inc, Shiga,
Japan) as previously described.7 Phenotype of TD cells was assessed by FACS 3 days after
transduction, and used as targets in 51Cr assays.
Immunophenotyping
T cell subset distribution was analyzed after the third stimulation by staining with
fluorochrome-conjugated antibodies for CD3–APC, CD4–PE, CD8–PerCP and CD56–
FITC. Transduction efficiency was analyzed by staining cells with CD3–FITC and CD19–
APC antibodies. All antibodies were from BD Biosciences, San Jose, CA, USA, or
Beckman Coulter, Brea, CA, USA; data acquisition was performed on a FACSCalibur (BD
Biosciences) using CellQuest Software (BD Biosciences) and data analysis was performed
using FlowJo Software (Treestar, Ashland, OR, USA). To evaluate CD107a/b degranulation,
T cells at the end of the third antigen-specific stimulation were resuspended at 1 × 106 cells
ml–1 in complete media with 10% fetal bovine serum (HyClone) without cytokines. After
blocking protein transport (GolgiPlug and GolgiStop, both from BD), following the
manufacturer's instruction, cells were stained with FITC-conjugated CD107a and CD107b
(both from BD), and then stimulated with either relevant or irrelevant pepmixes or single
peptides (5 μM) for 4–5 h at 37 °C at 5% CO2. Phorbol myristate acetate (25 ng ml–1, Sigma-
Aldrich, St. Louis, MO, USA) and ionomycin (1 μg ml–1, Sigma-Aldrich) were used as
positive controls. Cells were then collected, fixed for 10 min in 1% Cytofix (BD), washed
and then stained for 30 min with CD3–APC, CD4–PE and CD8–PerCP or appropriate
isotype controls. After washing, cells were analyzed on the FACSCalibur.
ELISpot assay
The IFN-γ ELISpot assay was performed as previously described.18 In brief, 1 × 105 T cells
per well were plated in triplicates and then stimulated with 5 μM of the specific pepmixes of
the single peptides or media alone. As positive control, T cells were stimulated with 25 ng
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ml–1 of phorbol myristate acetate and 1 mg ml–1 of ionomycin. The IFN-γ SFCs were
enumerated (ZellNet, Fort Lee, NJ, USA). T cell lines were defined as being reactive when
the number of SFCs was ≥2× above background level (media control or irrelevant pepmix).
Chromium-release assay
The cytotoxic activity of T cells was evaluated using a standard 6-h 51Cr-release assay, as
previously described.18 After labeling with 51Cr, target cells were incubated with T cells at
different E:T ratios in medium alone or in 1% Triton X-100 (Sigma-Aldrich) to determine
spontaneous and maximum 51Cr-release, respectively. The mean percentage of specific lysis
of triplicate wells was calculated as follows: ((test counts – spontaneous counts)/(maximum
counts – spontaneous counts)) × 100%.
Statistical analysis
Data were summarized by means and s.d. Student's t-test was used to determine the
statistically significant differences between the samples, with P-value <0.05 indicating a
significant difference. When multiple comparison analyses were required, statistical
significance was evaluated by a repeated measures ANOVA, followed by a Newman–Keuls
test for multiple comparisons. The exact binomial method was used to calculate the
confidence interval.
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T cell lines produce IFN-γ upon antigenic stimulation. After three antigen-specific
stimulations with pepmix-pulsed dendritic cells, T cell lines were analyzed for IFN-γ
production by ELISpot in response to media (gray bars), relevant pepmix (black bars) or
irrelevant pepmix (white bars). IFN-γ SFCs per 1 × 105 CTLs from (a) cytomegalovirus
(CMV) pp65 lines, (b) PRAME lines, (c) 2A-TAV lines and (d) 2A-ERAV lines are shown
(mean±s.d. of triplicates). The 2A-TAV lines from donors nos. 8, 9, 13, 14 and 15 were
reactive against the 2A-TAV pepmix with SFCs ≥2× above media or irrelevant pepmix (*),
and therefore selected for further analyses.
Arber et al. Page 8














T cell lines contain a mixture of CD4+ and CD8+ T cells. The phenotypes of the T cell lines
were analyzed by flow cytometry after three antigen-specific stimulations. All lines
contained a mixture of CD4+ and CD8+ T cells, with some admixed CD3–CD56+ NK cells.
Shown are mean±s.d. of percentage of positive cells for CMV-pp65 lines (n=7, black bars),
for PRAME lines (n=7, white bars), for 2A-TAV lines (n=14, light gray bars) and for 2A-
ERAV lines (n=9, dark gray bars). We found a trend for a lower proportion of CD8+ T cells
in 2A-TAV and 2A-ERAV lines (P=0.07) as compared with CMV-pp65 or PRAME lines.
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Lack of cytotoxic activity of 2A2A-TAV-specific T cells despite low levels of IFN-γ
production. (a) The 2A-TAV pepmix-reactive T cell lines from donors nos. 8, 9, 13, 14 and
15 were analyzed by IFN-γ ELISpot against the single 15-mer peptides contained in the 2A-
TAV pool (peptides p no. 1-p no. 11, colored bars) or no peptide (gray bar, mean±s.d. of
triplicates). Weak reactivity was found in 2A-TAV lines against the shown single peptides.
Donor no. 8 only showed nonspecific reactivity. (b) Representative FACS plots of the
CD107a/b degranulation assay (gated on CD3+ cells) from a pp65-specific CTL line, a
PRAME-specific CTL line and a 2A-TAV-specific CTL line stimulated with irrelevant (2A-
ERAV) or relevant (pp65, PRAME or 2A-TAV) pepmixes, 2A-TAV peptide no. 5 (p no. 5)
or phorbol myristate acetate (PMA)/ionomycin (positive control). (c) Summary of CD107a/b
degranulation assay for 2A-TAV CTLs (n=4) and pp65/PRAME CTLs (n=9) (mean±s.d. of
% CD107a/b+CD3+ cells). (d) Summary of transduction efficiency of SFG.iCasp9.2A-
TAV.ΔCD19-TD T cells from donors no. 9, and 13–15 (mean±s.d. of % CD19+CD3+ cells).
(e) Summary of 51Cr-release assay of 2A-TAV-specific CTLs from donors no. 9, and 13–15
tested against non-transduced (NT) or 2A-TAV TD autologous T cells (mean±s.d. of %
specific lysis) at an E:T ratio of 20:1.
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2A sequences are contained in polycistronic retroviral vectors. (a) The 2A-TAV sequence
and the single overlapping 15-mer peptides (no. 1–11) were derived from the
SFG.iCasp9.2A-TAV.ΔCD19 retroviral vector.13 (b) The 2A-ERAV sequence and the
single overlapping 15-mer peptides (no. 1–11) were derived from the SFG.iCasp9.2A-
TAV.CAR19-28ζ.2A-ERAV.optIL15 retroviral vector.7
Arber et al. Page 11

























Arber et al. Page 12
Table 1
Donor HLA typing
HLA/donor HLA-A2 FACS HLA-A HLA-B HLA-DRB1 HLA-DQB1
1 Pos na na na na
2 Pos na na na na
3 Neg na na na na
4 Pos *02, — *07,*15 *13, — *03, *06
5 Pos *02, *03 *51, — *04, *07 *02, *03
6 Neg na na na na
7 Neg na na na na
8 Pos *02, *03 *07, *35 *07, *09 *02, —
9 Pos *02, *23 *07, *18 *11,*13 *03, *06
10 Pos *02 *68 *07, *51 *04, *15 *03, *06
11 Pos *02, — *42, *53 *01, *08 *04, *05
12 Pos *02, *33 *42, *58 *11, *13 *03, *06
13 Pos *02, *03 *14, *44 *04, — *03, —
14 Pos *02, *23 *44, *51 *04, *14 *03, *05
15 Pos *02, *29 *44, — *03, *11 *02, *03
16 Pos *02, — *35, — *04, *08 *03, *04
Abbreviations: HLA, human leukocyte antigen; na, not available; Neg, negative; Pos, positive. In bold, 2A-TAV-reactive donors.
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